Ongoing COVID-19 lockdowns and requirements of social distancing have swiftly pushed healthcare provision and patient monitoring towards remote options. Even though remote patient monitoring (RPM) was already being used before the start of the pandemic, the uptake of the technology was relatively low, primarily used to ensure better post-acute care and management of chronic conditions. However, now the technology is uniquely positioned to lead to a fundamental change in healthcare services delivery and clinical trials, says GlobalData.
Their latest report, ‘The State of the Biopharmaceutical Industry 2021’, reveals that RPM is expected to become the industry trend with the most impact on the pharmaceutical industry in 2021, as confirmed by 20% of 198 pharmaceutical industry professionals.
Urte Jakimaviciute MSc, Senior Director of Market Research, commented, “Despite much lower uptake in previous years, RPM got off to a strong start and witnessed a massive uptake in the life-sciences sector in 2020. With more patients, payers, and physicians getting accustomed to virtual interactions, RPM will continue to transform healthcare delivery and accelerate adoption of decentralized/virtual clinical trials. The COVID-19 outbreak provided a unique opportunity for RPM to gain widespread acceptance, demonstrate value, and subsequently become a ‘new normal’ across healthcare and pharmaceutical fields.”
With increasing numbers of patients, clinical practices and pharmaceutical companies getting hands-on experience with RPM, the adoption of remote monitoring tools is on course to remain solid even after COVID-19 recedes.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.